Literature DB >> 19833129

Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover.

Sylvia S Dias1, Carol Hogan, Anna-Maria Ochocka, David W Meek.   

Abstract

The E3 ubiqutin ligase, murne double-minute clone 2 (MDM2), promotes the degradation of p53 under normal homeostatic conditions. Several serine residues within the acidic domain of MDM2 are phosphorylated to maintain its activity but become hypo-phosphorylated following DNA damage, leading to inactivation of MDM2 and induction of p53. However, the signalling pathways that mediate these phosphorylation events are not fully understood. Here we show that the oncogenic and cell cycle-regulatory protein kinase, polo-like kinase-1 (PLK1), phosphorylates MDM2 at one of these residues, Ser260, and stimulates MDM2-mediated turnover of p53. These data are consistent with the idea that deregulation of PLK1 during tumourigenesis may help suppress p53 function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833129     DOI: 10.1016/j.febslet.2009.09.057

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

1.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

2.  Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis.

Authors:  Travis L Schmit; Minakshi Nihal; Mary Ndiaye; Vijayasaradhi Setaluri; Vladimir S Spiegelman; Nihal Ahmad
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

3.  Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Sankaranarayanan Kannan; Marisa J L Aitken; Shelley M Herbrich; Leonard S Golfman; Mandy G Hall; Duncan H Mak; Jared K Burks; Guangchun Song; Marina Konopleva; Charles G Mullighan; Joya Chandra; Patrick A Zweidler-McKay
Journal:  Mol Cancer Ther       Date:  2019-06-21       Impact factor: 6.261

4.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

Authors:  Long Chen; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 5.  Multitasking with ubiquitin through multivalent interactions.

Authors:  Fen Liu; Kylie J Walters
Journal:  Trends Biochem Sci       Date:  2010-02-22       Impact factor: 13.807

6.  Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Authors:  Brian D Cholewa; Mary A Ndiaye; Wei Huang; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Lett       Date:  2016-10-25       Impact factor: 8.679

7.  G Protein-coupled receptor kinase 5 is localized to centrosomes and regulates cell cycle progression.

Authors:  Allison M Michal; Christopher H So; Neil Beeharry; Haripriya Shankar; Rouzbeh Mashayekhi; Timothy J Yen; Jeffrey L Benovic
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

Review 8.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

Review 9.  The role of polo-like kinase 1 in carcinogenesis: cause or consequence?

Authors:  Brian D Cholewa; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Res       Date:  2013-11-21       Impact factor: 12.701

10.  HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Authors:  Angela M Sosin; Angelika M Burger; Aisha Siddiqi; Judith Abrams; Ramzi M Mohammad; Ayad M Al-Katib
Journal:  J Hematol Oncol       Date:  2012-09-18       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.